Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec® capsules

被引:30
作者
Ivanovic, D
Medenica, M
Jancic, B
Malenovic, A
机构
[1] Fac Pharm Belgrade, Dept Chem Phys, YU-11000 Belgrade, Serbia
[2] Fac Pharm Belgrade, Dept Drug Anal, YU-11000 Belgrade, Serbia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2004年 / 800卷 / 1-2期
关键词
imatinib mesylate;
D O I
10.1016/j.jchromb.2003.10.018
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for the simultaneous determination of imatinib mesylate and of the impurity product in Glivec(R) capsules (Novartis, Switzerland). Separations were performed on a X Terra(TM) 150 mm 4.6 mm, 5 mum particle size column at 25 degreesC. The mobile phase was a mixture of methanol-water-triethylamine (25:74: 1, v/v/v) with flow rate of 1.0 ml min(-1). pH value of water-triethylamine (TEA) was adjusted to 2.4 with orthophosphoric acid before adding of methanol. UV detection was performed at 267 nm. Acetaminophen was used as an internal standard. The method was validated statistically for its selectivity, linearity, precision, accuracy and robustness. Due to its speed and accuracy, the method may be used for quality control analyses. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 10 条
[1]
High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Lohne, J ;
Ramos, L ;
Khemani, L ;
Hayes, M ;
Tse, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :325-340
[2]
Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Khemani, L ;
Hayes, M ;
Bedman, T ;
Tse, F .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1183-1194
[3]
*COUNC EUR, 1999, EUROPEAN PHARMACOPEI
[4]
DOLAN JW, 1996, LC GC INT JUL, P400
[5]
DOLAN JW, 1999, LC GC EUR, V12, P156
[6]
DOUGLAS CM, 1976, DESIGN ANAL EXPT, P340
[7]
FDA licences imatinib mesylate for CML [J].
Habeck, M .
LANCET ONCOLOGY, 2002, 3 (01) :6-6
[8]
Robustness testing of a reversed-phase high-performance liquid chromatographic assay: comparison of fractional and asymmetrical factorial designs [J].
Hund, E ;
Vander Heyden, Y ;
Haustein, M ;
Massart, DL ;
Smeyers-Verbeke, J .
JOURNAL OF CHROMATOGRAPHY A, 2000, 874 (02) :167-185
[9]
1996, P 3 INT C HARM TECHN
[10]
2003, CAS REGISTRY DATABAS